Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Betacoronavirus
COVID-19
Child
Communicable Disease Control
/ methods
Coronavirus Infections
/ epidemiology
Female
Humans
Immunoglobulin G
/ blood
Italy
/ epidemiology
Male
Middle Aged
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Seroepidemiologic Studies
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
08
2020
accepted:
09
11
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Through a hospital-based SARS-CoV-2 molecular and serological screening, we evaluated the effectiveness of two months of lockdown and two of surveillance, in Milan, Lombardy, the first to be overwhelmed by COVID-19 pandemics during March-April 2020. All subjects presenting at the major hospital of Milan from May-11 to July-5, 2020, underwent a serological screening by chemiluminescent assays. Those admitted were further tested by RT-PCR. The cumulative anti-N IgG seroprevalence in the 2753 subjects analyzed was of 5.1% (95%CI = 4.3%-6.0%), with a peak of 8.4% (6.1%-11.4%) 60-63 days since the peak of diagnoses (March-20). 31/106 (29.2%) anti-N reactive subjects had anti-S1/S2 titers >80 AU/mL. Being tested from May-18 to June-5, or residing in the provinces with higher SARS-CoV-2 circulation, were positively and independently associated with anti-N IgG reactivity (OR [95%CI]: 2.179[1.455-3.264] and 3.127[1.18-8.29], respectively). In the 18 RT-PCR positive, symptomatic subjects, anti-N seroprevalence was 33.3% (95% CI: 14.8%-56.3%). SARS-CoV-2 seroprevalence in Milan is low, and in a downward trend after only 60-63 days since the peak of diagnoses. Italian confinement measures were effective, but the risk of contagion remains concrete. In hospital-settings, the performance of molecular and serological screenings upon admission remains highly advisable.
Identifiants
pubmed: 33216817
doi: 10.1371/journal.pone.0242765
pii: PONE-D-20-24967
pmc: PMC7679019
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242765Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Microbiol Infect. 2020 Jun 25;:
pubmed: 32593741
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71
pubmed: 15013989
Clin Microbiol Infect. 2020 Jun 9;:
pubmed: 32531475
J Med Virol. 2020 Jun 2;:
pubmed: 32484942
Clin Infect Dis. 2020 Jun 16;:
pubmed: 32556191
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
J Clin Microbiol. 2005 Jul;43(7):3054-8
pubmed: 16000415
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
JAMA. 2020 May 19;323(19):1881-1883
pubmed: 32301958
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404